Review
Medicine, Research & Experimental
Paul Andrei Negru, Andrei-Flavius Radu, Cosmin Mihai Vesa, Tapan Behl, Mohamed M. Abdel-Daim, Aurelia Cristina Nechifor, Laura Endres, Manuela Stoicescu, Bianca Pasca, Delia Mirela Tit, Simona Gabriela Bungau
Summary: A comprehensive comparative assessment of FVP and RDV against SARS-CoV-2 infections was conducted, emphasizing the importance of understanding the interactions between drug molecules and infectious agents to improve the management of COVID-19 patients and reduce the risk of antiviral resistance.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Immunology
Frederick G. Hayden, Robert P. Lenk, Lucille Stonis, Catherine Oldham-Creamer, Lih Lisa Kang, Carol Epstein
Summary: We conducted double-blind, placebo-controlled trials to assess the efficacy and tolerability of favipiravir in acute influenza. The results showed that favipiravir significantly reduced the time to illness alleviation and viral titers, but had inconsistent effects on alleviating symptoms. Further studies on higher doses and antiviral combinations are needed for treating severe influenza and other RNA viral infections.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Microbiology
Jennifer Mayor, Olivier Engler, Sylvia Rothenberger
Summary: Ecological changes, population movements, and increasing urbanization contribute to the spread of hantaviruses, posing a high risk of virus transmission and diseases to humans; Ribavirin is currently the only antiviral medication used to treat HFRS caused by HTNV, but with severe side effects; Favipiravir has shown similar potent antiviral activity on HTNV infection, and when used in combination with low-dose ribavirin, its efficacy is enhanced, suggesting the potential for improved treatment.
Article
Chemistry, Analytical
Rasha M. K. Mohamed, Sabrein H. Mohamed, Aml M. Asran, Ibrahim H. Alsohaimi, Hassan M. A. Hassan, Hossieny Ibrahim, Mohamed M. El-Wekil
Summary: A novel electrochemical sensing platform based on gold nanoparticles anchored conductive carbon black modified graphite nanopowder flakes paste electrode was developed for the detection of Favipiravir (FVP). The sensor exhibited excellent sensitivity, stability, and anti-interference capability, allowing simultaneous detection of FVP and co-administered drug paracetamol (PCT). The detection limits for FVP and PCT were 7.5 nM and 4.3 nM, respectively. The sensor was successfully applied for simultaneous detection of FVP and PCT in spiked human plasma and pharmaceutical preparations, as well as in the presence of ascorbic acid in a real sample.
MICROCHEMICAL JOURNAL
(2023)
Article
Immunology
Yoav Golan, Jesus Abraham Simon Campos, Rob Woolson, Donald Cilla, Rodolfo Hanabergh, Yaneicy Gonzales-Rojas, Reynaldo Lopez, Robert Finberg, Armand Balboni
Summary: This double-blind randomized controlled trial demonstrates that favipiravir is not effective in mitigating COVID-19 symptoms, preventing disease progression, and stopping viral shedding.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Immunology
Frederick G. Hayden, Robert P. Lenk, Carol Epstein, Lih Lisa Kang
Summary: This study reveals the pharmacokinetics of oral favipiravir and its relationship to antiviral effects in influenza. Higher levels of favipiravir (>20ug/ml) are associated with better antiviral effects and faster alleviation of symptoms.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Chemistry, Medicinal
Andrew J. Prussia, Spandan Chennamadhavuni
Summary: SARS-CoV-2 replication relies on RNA-dependent RNA polymerase (RdRp), and nucleoside analogs like Remdesivir may inhibit its function. Recent Cryo-EM structures provide insights into the viral replication mechanism, potentially guiding the development of novel drugs for COVID-19 treatment.
JOURNAL OF CHEMICAL INFORMATION AND MODELING
(2021)
Article
Pharmacology & Pharmacy
Masanori Baba, Mika Okamoto, Masaaki Toyama, Norikazu Sakakibara, Masayuki Shimojima, Masayuki Saijo, Takuro Niwa, Yoshiki Yagi
Summary: A compound, C-90, was identified as a selective inhibitor of SFTSV virus replication but had poor oral bioavailability. Two other compounds with selective anti-SFTSV activity and improved pharmacokinetics in vivo were further designed and synthesized.
ANTIVIRAL RESEARCH
(2023)
Article
Virology
Michele Bengue, Ai-rada Pintong, Florian Liegeois, Antoine Nougairede, Rodolphe Hamel, Julien Pompon, Xavier de Lamballerie, Pierre Roques, Valerie Choumet, Dorothee Misse
Summary: Mayaro virus (MAYV) infection is a significant health issue without a specific antiviral treatment, but Favipiravir has shown potential in inhibiting viral activity.
Article
Biochemistry & Molecular Biology
Mengyuan Xu, Xi Li, Huiying Zheng, Jiehan Chen, Xiaohua Ye, Tiantian Liu
Summary: Nanomaterial technology has gained attention for its antibacterial and drug delivery abilities. Metal-organic frameworks (MOFs) have advantages such as pore structure, large surface area, metal sites, and stability, making them ideal for drug encapsulation and adsorption. The synthesis of a novel complex MIL-101(Fe)-T705 resulted in inhibition of Staphylococcus aureus growth and effective antiviral activity against influenza A virus, with good biosafety and higher efficacy compared to individual components MIL-101(Fe) and T-705.
Article
Pharmacology & Pharmacy
Jonna B. Westover, Shibani Naik, Kevin W. Bailey, Luci Wandersee, Vidyasagar R. Gantla, Brady T. Hickerson, Ken McCormack, Greg Henkel, Brian B. Gowen
Summary: This study evaluated the efficacy of ARN-75039, a fusion inhibitor, against pathogenic JUNV in a guinea pig infection model. The compound showed significant protection even when administered 6 days after viral challenge, suggesting a potential therapeutic option for mammarenaviral hemorrhagic fevers. Additionally, combination treatment of ARN-75039 with favipiravir resulted in improved survival outcomes in JUNV-challenged guinea pigs.
ANTIVIRAL RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Ayca Yildiz Pekoz, Ozlem Akbal Dagistan, Hanan Fael, Meltem Culha, Aybige Erturk, Nur Sena Basarir, Gokben Sahin, Muge Serhatli, Gamze Cakirca, Saban Tekin, Leyla Semiha Sen, Mustafa Sevim, Lutfiye Mulazimoglu Durmusoglu, Berrak C. Yegen
Summary: This study developed and characterized an inhalation solution of favipiravir at a concentration of 2 mg/mL for the treatment of patients with COVID-19. The solution showed superior stability in phosphate buffer saline (PBS) and demonstrated minimum toxicity and sufficient antiviral activity at a concentration of 2 mg/mL. The study suggests that the favipiravir solution prepared with PBS could be a suitable and promising inhalation formulation for pulmonary delivery in the treatment of COVID-19 patients.
Article
Virology
Evelyn J. Franco, Camilly P. Pires de Mello, Ashley N. Brown
Summary: The study evaluated the antiviral potential of UV-4B, IFN, SOF, and FAV against Dengue virus, finding that UV-4B and IFN showed antiviral potential against DENV in multiple physiologically relevant cell types.
Article
Microbiology
Evelyn J. Franco, Kaley C. Hanrahan, Ashley N. Brown
Summary: This study evaluates the antiviral potential of favipiravir (FAV) against Zika virus (ZIKV) in three human cell lines. FAV showed the strongest activity in HeLa cells, with exposure time affecting the decline in viral infectivity. Toxicity studies showed no harm to the cells and FAV even improved the viability of infected HeLa cells.
Article
Pharmacology & Pharmacy
Thomas Tipih, Kimberly Meade-White, Deepashri Rao, Trenton Bushmaker, Mathew Lewis, Carl Shaia, Heinz Feldmann, David W. Hawman
Summary: A study describes a lethal model of CCHFV infection using mice and evaluates the protective efficacy of different drugs. Favipiravir and ribavirin are found to protect mice from clinical disease and death, although CCHFV RNA persists in survivors.
ANTIVIRAL RESEARCH
(2023)